JP Morgan has upgraded Recursion Pharmaceuticals Inc (RXRX) to Overweight from Neutral, a move that reflects a more optimistic view on the company's prospects. This change in analyst sentiment may indicate improved fundamentals or better-than-expected business performance.
Recursion Pharmaceuticals, a clinical-stage biotechnology firm based in Salt Lake City, Utah, employs 840 full-time staff. The company focuses on discovering novel medicines through automation, artificial intelligence, and machine learning. Its platform, the Recursion Operating System (OS), integrates diverse technologies to map and navigate complex biological relationships.
As of December 16, 2025, Recursion Pharmaceuticals has a market capitalisation of $2.2 billion and an earnings per share (EPS) of -1.81. The firm is preparing for upcoming earnings reports, with estimates for August 3, 2026, projecting an EPS of -0.35 and revenue of $18.3 million.
Analyst ratings are based on extensive research and financial models, serving as one of many inputs for investment decisions. The current consensus among analysts is a Buy, with 2 Strong Buy, 5 Buy, and 7 Hold ratings recorded as of December 1, 2025. Notably, this upgrade adds to the recent positive momentum following a Q3 2025 earnings surprise, where the EPS was -0.36 against an estimate of -0.38.
This update provides insight into the evolving perceptions of Recursion Pharmaceuticals' market position and potential growth trajectory.